ZA201708387B - 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor - Google Patents
2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptorInfo
- Publication number
- ZA201708387B ZA201708387B ZA2017/08387A ZA201708387A ZA201708387B ZA 201708387 B ZA201708387 B ZA 201708387B ZA 2017/08387 A ZA2017/08387 A ZA 2017/08387A ZA 201708387 A ZA201708387 A ZA 201708387A ZA 201708387 B ZA201708387 B ZA 201708387B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzoxazin
- modulators
- dihydro
- receptor
- derivatives
- Prior art date
Links
- YBYIZRPBXCCDQW-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazin-4-one Chemical class C1=CC=C2C(=O)NCOC2=C1 YBYIZRPBXCCDQW-UHFFFAOYSA-N 0.000 title 1
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title 1
- 230000001713 cholinergic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015129043 | 2015-06-26 | ||
| JP2015206797 | 2015-10-20 | ||
| PCT/JP2016/069189 WO2016208775A1 (en) | 2015-06-26 | 2016-06-23 | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201708387B true ZA201708387B (en) | 2019-05-29 |
Family
ID=56799518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/08387A ZA201708387B (en) | 2015-06-26 | 2017-12-11 | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9878989B2 (enExample) |
| EP (1) | EP3313836B1 (enExample) |
| JP (1) | JP6745824B2 (enExample) |
| KR (1) | KR20180019234A (enExample) |
| CN (1) | CN107922403A (enExample) |
| AU (1) | AU2016284654B9 (enExample) |
| CA (1) | CA2988572A1 (enExample) |
| CL (1) | CL2017003127A1 (enExample) |
| CO (1) | CO2017012859A2 (enExample) |
| CR (1) | CR20170568A (enExample) |
| DO (1) | DOP2017000309A (enExample) |
| EA (1) | EA201890152A1 (enExample) |
| HK (1) | HK1248698A1 (enExample) |
| IL (1) | IL256059A (enExample) |
| MX (1) | MX2017016875A (enExample) |
| PE (1) | PE20180500A1 (enExample) |
| PH (1) | PH12017502351A1 (enExample) |
| TN (1) | TN2017000508A1 (enExample) |
| TW (1) | TW201710255A (enExample) |
| UA (1) | UA121503C2 (enExample) |
| UY (1) | UY36750A (enExample) |
| WO (1) | WO2016208775A1 (enExample) |
| ZA (1) | ZA201708387B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3313836B1 (en) * | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| WO2016206101A1 (en) | 2015-06-26 | 2016-12-29 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017155050A1 (ja) | 2016-03-11 | 2017-09-14 | 武田薬品工業株式会社 | 芳香環化合物 |
| CN118005619A (zh) * | 2017-02-28 | 2024-05-10 | 武田药品工业株式会社 | 用于生产杂环化合物的方法 |
| WO2018194181A1 (en) | 2017-04-18 | 2018-10-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
| JP7197472B2 (ja) | 2017-05-19 | 2022-12-27 | 武田薬品工業株式会社 | スクリーニング方法 |
| US11236099B2 (en) | 2017-06-20 | 2022-02-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR102658949B1 (ko) | 2017-06-20 | 2024-04-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 |
| JP7443238B2 (ja) * | 2018-09-28 | 2024-03-05 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3113227A1 (en) | 2018-09-28 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US12162864B2 (en) | 2018-09-28 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Condensed-cyclic compound |
| KR102288434B1 (ko) * | 2018-10-18 | 2021-08-12 | 에이치케이이노엔 주식회사 | 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도 |
| EP3870173A4 (en) | 2018-10-24 | 2022-06-22 | Vanderbilt University | WDR5 INHIBITORS AND MODULATORS |
| US12577227B2 (en) * | 2019-06-04 | 2026-03-17 | Vanderbilt University | WDR5 inhibitors and modulators |
| US12692249B2 (en) | 2019-11-08 | 2026-07-28 | Vanderbilt University | WDR5 inhibitors and modulators |
| CN114539035B (zh) * | 2021-03-10 | 2023-08-18 | 山东新时代药业有限公司 | 一种七氟烷的合成方法 |
| WO2025227116A1 (en) * | 2024-04-25 | 2025-10-30 | The Board Of Regents Of The University Of Texas System | Eph-ephrin tetramerization inhibitors that target a previously unknown and very high-affinity chelator-type intermolecular protein-protein interaction |
| WO2025231260A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2025231259A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| EP0597956A1 (en) | 1991-07-29 | 1994-05-25 | Warner-Lambert Company | Quinazoline derivatives as acetylcholinesterase inhibitors |
| IT1255179B (it) | 1992-06-26 | 1995-10-20 | Enzo Cereda | Azaciclo e azabiciclo alchiliden idrossilamine |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| AU2231199A (en) | 1998-01-16 | 1999-08-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Alkenyldiarylmethane non-nucleoside hiv-1 reverse transcriptase inhibitors |
| YU47600A (sh) | 1998-01-27 | 2002-09-19 | Aventis Pharmaceuticals Products Inc. | SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa |
| JP2003529531A (ja) | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルＸａ因子阻害剤 |
| KR20020087041A (ko) | 1999-07-28 | 2002-11-21 | 아벤티스 파마슈티칼스 프로덕츠 인크. | 치환된 옥소아자헤테로사이클릴 화합물 |
| JP2001131173A (ja) | 1999-08-23 | 2001-05-15 | Kyorin Pharmaceut Co Ltd | 二環式複素環誘導体 |
| JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| WO2002003684A2 (en) | 2000-06-30 | 2002-01-10 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| JP2004532200A (ja) | 2001-03-15 | 2004-10-21 | サエジス ファーマシューティカルズ， インコーポレイテッド | 全身性ストレスの後に認識機能を回復するための方法 |
| US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| US20030004913A1 (en) | 2001-07-02 | 2003-01-02 | Koninklijke Philips Electronics N.V. | Vision-based method and apparatus for detecting an event requiring assistance or documentation |
| WO2003045315A2 (en) | 2001-11-26 | 2003-06-05 | Cortex Pharmaceuticals, Inc. | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| WO2004073639A2 (en) | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| CN1777425A (zh) | 2003-03-28 | 2006-05-24 | 阿卡蒂亚药品公司 | 用于疼痛控制的毒蕈碱性m1受体激动剂 |
| US20040266659A1 (en) | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
| GB0504019D0 (en) | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
| US20090156581A1 (en) | 2005-04-15 | 2009-06-18 | Board Of Trustrees Of Michigan State University | Aminergic pharmaceutical compositions and methods |
| GB0516570D0 (en) | 2005-08-12 | 2005-09-21 | Astrazeneca Ab | Amide derivatives |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| WO2007044937A2 (en) | 2005-10-13 | 2007-04-19 | President And Fellows Of Harvard College | Compositions and methods to modulate memory |
| RS55630B1 (sr) | 2005-12-21 | 2017-06-30 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
| GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US7834023B2 (en) | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
| ZA200904826B (en) * | 2007-01-03 | 2010-09-29 | Cortex Pharma Inc | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
| US8618074B2 (en) | 2007-03-15 | 2013-12-31 | Board Of Regents Of The University Of Texas System | GPCR enhanced neuroprotection to treat brain injury |
| EP2195317B1 (en) | 2007-08-29 | 2012-01-18 | Schering Corporation | 2,3-substituted azaindole derivatives for treating viral infections |
| RU2010111550A (ru) | 2007-08-29 | 2011-10-10 | Шеринг Корпорейшн (US) | 2,3-замещенные индольные производные для лечения вирусных инфекций |
| WO2009032124A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | Substituted indole derivatives and methods of use thereof |
| NO2200610T3 (enExample) | 2007-09-21 | 2018-06-09 | ||
| WO2009039461A2 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| US8765757B2 (en) | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| CN102317285A (zh) | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
| US20110024198A1 (en) | 2008-02-19 | 2011-02-03 | Baker Hughes Incorporated | Bearing systems containing diamond enhanced materials and downhole applications for same |
| WO2010042603A1 (en) | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
| US8557832B2 (en) | 2008-11-20 | 2013-10-15 | Merck Sharp & Dohme Corp. | Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators |
| JP2012518640A (ja) | 2009-02-23 | 2012-08-16 | メルク・シャープ・エンド・ドーム・コーポレイション | ピラゾロ［４，３−ｃ］シンノリン−３−オンＭ１受容体陽性アロステリックモジュレーター |
| WO2010102218A1 (en) | 2009-03-05 | 2010-09-10 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| EP2421366B1 (en) | 2009-04-20 | 2013-08-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
| ES2353093B1 (es) | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| ES2742728T3 (es) | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| CN102480964B (zh) | 2009-08-31 | 2015-07-08 | 默沙东公司 | 吡喃基芳基甲基苯并喹唑啉酮m1受体正向别构调节剂 |
| US8895580B2 (en) | 2009-10-21 | 2014-11-25 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone M1 receptor positive allosteric modulators |
| WO2011075371A1 (en) | 2009-12-14 | 2011-06-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| WO2011084371A1 (en) | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
| US8557992B2 (en) | 2010-06-15 | 2013-10-15 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators |
| EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| WO2012047702A1 (en) * | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
| US9549928B2 (en) | 2011-04-29 | 2017-01-24 | The University Of Toledo | Muscarinic agonists as enhancers of cognitive flexibility |
| US9284312B2 (en) * | 2011-05-17 | 2016-03-15 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators |
| WO2012170599A1 (en) | 2011-06-10 | 2012-12-13 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| JP6075408B2 (ja) | 2012-11-22 | 2017-02-08 | 株式会社デンソー | 物標検出装置 |
| EP2938600B1 (en) | 2012-12-27 | 2017-01-25 | F. Hoffmann-La Roche AG | Comt inhibitors |
| CN104955826B (zh) | 2013-02-04 | 2019-05-31 | 默克专利股份公司 | 可用于治疗神经学疾病和病症的螺-喹唑酮衍生物 |
| US10738024B2 (en) | 2013-05-06 | 2020-08-11 | Indiana University Research And Technology Corporation | Compounds for treatment of angiogenesis-mediated diseases |
| JP6063400B2 (ja) | 2014-01-08 | 2017-01-18 | 株式会社日立ビルシステム | エレベータの異常監視装置 |
| ES2811088T3 (es) | 2014-04-23 | 2021-03-10 | Takeda Pharmaceuticals Co | Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer |
| JP6531093B2 (ja) | 2014-05-16 | 2019-06-12 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| EP3156397B1 (en) | 2014-06-13 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| EP3313836B1 (en) * | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| WO2017044693A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017155050A1 (ja) | 2016-03-11 | 2017-09-14 | 武田薬品工業株式会社 | 芳香環化合物 |
| WO2018122845A1 (en) | 2016-12-29 | 2018-07-05 | Rvx Therapeutics Ltd. | Methods and compositions for potentiating cns drugs and reducing their side effects |
-
2016
- 2016-06-23 EP EP16756814.6A patent/EP3313836B1/en active Active
- 2016-06-23 CA CA2988572A patent/CA2988572A1/en not_active Abandoned
- 2016-06-23 TW TW105119717A patent/TW201710255A/zh unknown
- 2016-06-23 MX MX2017016875A patent/MX2017016875A/es unknown
- 2016-06-23 UY UY0001036750A patent/UY36750A/es not_active Application Discontinuation
- 2016-06-23 WO PCT/JP2016/069189 patent/WO2016208775A1/en not_active Ceased
- 2016-06-23 CR CR20170568A patent/CR20170568A/es unknown
- 2016-06-23 TN TNP/2017/000508A patent/TN2017000508A1/en unknown
- 2016-06-23 KR KR1020187002502A patent/KR20180019234A/ko not_active Withdrawn
- 2016-06-23 US US15/190,642 patent/US9878989B2/en active Active
- 2016-06-23 JP JP2017567489A patent/JP6745824B2/ja active Active
- 2016-06-23 EA EA201890152A patent/EA201890152A1/ru unknown
- 2016-06-23 PE PE2017002792A patent/PE20180500A1/es unknown
- 2016-06-23 AU AU2016284654A patent/AU2016284654B9/en not_active Ceased
- 2016-06-23 CN CN201680048681.6A patent/CN107922403A/zh active Pending
- 2016-06-23 UA UAA201800653A patent/UA121503C2/uk unknown
- 2016-06-23 US US15/735,418 patent/US10323027B2/en active Active
- 2016-06-23 HK HK18108309.9A patent/HK1248698A1/zh unknown
-
2017
- 2017-10-31 US US15/799,379 patent/US10087150B2/en active Active
- 2017-12-03 IL IL256059A patent/IL256059A/en unknown
- 2017-12-07 CL CL2017003127A patent/CL2017003127A1/es unknown
- 2017-12-11 ZA ZA2017/08387A patent/ZA201708387B/en unknown
- 2017-12-14 CO CONC2017/0012859A patent/CO2017012859A2/es unknown
- 2017-12-18 PH PH12017502351A patent/PH12017502351A1/en unknown
- 2017-12-26 DO DO2017000309A patent/DOP2017000309A/es unknown
-
2018
- 2018-08-27 US US16/113,635 patent/US10428056B2/en active Active
-
2019
- 2019-04-25 US US16/394,762 patent/US10899752B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256059A (en) | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor | |
| GB201913962D0 (en) | Ophthalmic drug compositions | |
| GB2536517B (en) | Opthalmic drug compositions | |
| MA41265A (fr) | Compositions pour administration de médicaments iléo-jéjunal. | |
| DK3406609T3 (da) | Bicykliske aza-forbindelser som muskariniske receptoragonister | |
| DK3221298T3 (da) | 4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139 | |
| DK3191450T3 (da) | Pyridonderivater som kinasehæmmere omarrangeret under transfektion (ret) | |
| MA54254A (fr) | Dérivés de benzodiazépine cytotoxique | |
| EP3325533A4 (en) | HARDENABLE BENZOXAZINE COMPOSITIONS | |
| EP3134185A4 (en) | Sunscreen compositions | |
| DK3325483T3 (da) | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater | |
| DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
| ZA201602890B (en) | Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| IL257869A (en) | Fluoroindole derivatives as positive allosteric modulators for muscarinic receptor am.1 | |
| EP3191541A4 (en) | Cationically curable benzoxazine compositions | |
| EP3285873A4 (en) | Substituted benzofuran derivatives as novel antimycobacterial agents |